ROVI updates its strategy in a meeting with shareholders, investors and analysts
Mié, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Relacionados
Los ingresos operativos aumentaron un 21%, hasta alcanzar los 177,5 millones de euros en el primer semestre de 2019, como resultado...
7 min
30/07/2019
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) ha informado hoy de la conclusión de los estudios PRISMA-31 y BORIS2, finalizando así el...
6 min
05/07/2019
La familia López-Belmonte, máximos accionistas de Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), ha ampliado su participación en el...
1 min
27/05/2019
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.